US FDA panel to review Wyeth's Prevnar 13 and Protein Sciences' flu vaccine
This article was originally published in Scrip
Executive Summary
The US FDA's vaccines advisory panel will review Wyeth's 13-valent pneumococcal vaccine, Prevnar 13, on November 18th. The advisors will also hear updates on the agency's H1N1 vaccine activities and postmarketing surveillance that same day.